Elevated fibrinogen-albumin ratio is an adverse prognostic factor for patients with primarily resected gastroesophageal adenocarcinoma
Journal of Cancer Research and Clinical Oncology · 2024
DOI: 10.1007/s00432-024-05976-z ↗At a glance
Journal article in Journal of Cancer Research and Clinical Oncology, 2024. Written by Gerd Jomrich and 9 co-authors. Institution: Department of General Surgery, Gastroesophageal Tumor Unit, Comprehensive Cancer Center (CCC), Medical University of Vienna, Vienna, Austria. Major MEDLINE topics: Fibrinogen, Adenocarcinoma, Esophageal Neoplasms, Stomach Neoplasms. Cited 3 times so far (Crossref); 34 references. The full text is freely available (open access, CC BY 4.0). Funded by: Medical University of Vienna.
Abstract (original language)
Purpose
Serum fibrinogen and albumin play important roles in systemic inflammation and are implicated in tumor progression. The fibrinogen-to-albumin ratio (FAR) has shown a prognostic impact in several malignancies. This study aims to assess the prognostic value of the pretherapeutic FAR in patients with adenocarcinoma of the gastroesophageal junction (AEG) who underwent upfront resection.
Methods
Consecutive patients who underwent surgical resection at the Department of Surgery at the Medical University of Vienna between 1992 and 2014 were included into this study. Optimal cut-off values were determined with the receiver-operating characteristic (ROC) curve, uni- and multivariate analyzes were calculated by the Cox proportional hazard regression model for overall survival (OS).
Results
Among 135 included patients, the majority were male (79.26%), with a mean age of 66.53 years. Elevated FAR correlated significantly ( p = 0.002) with shorter OS in univariate analysis, also confirmed as independent prognostic factor ( p = 0.005) in multivariable analysis. The ROC curve of FAR (AUC = 0.744) outperformed fibrinogen (AUC = 0.738) and albumin (AUC = 0.378) in predicting OS for AEG patients.
Conclusion
The FAR serves as an independent prognostic factor for OS in patients undergoing primarily resection for AEG. Given its routine availability and ease of calculation, FAR could help in diagnosis and treatment selection for AEG patients. Further validation studies are warranted to confirm these findings conclusively.
Subjects
MeSH terms (MEDLINE)
Author keywords
Substances
Authors and institutions
- Department of General Surgery, Gastroesophageal Tumor Unit, Comprehensive Cancer Center (CCC), Medical University of Vienna, Vienna, Austria.
- Vienna University of Economics and Business, Vienna, Austria.
- Department of Medicine 1, Division of Oncology, Gastroesophageal Tumor Unit, Medical University of Vienna, Comprehensive Cancer Center (CCC), Vienna, Austria.
- Department of Laboratory Medicine, Medical University of Vienna, Vienna, Austria.
- Department of General Surgery, Gastroesophageal Tumor Unit, Comprehensive Cancer Center (CCC), Medical University of Vienna, Vienna, Austria. sebastian.schoppmann@meduniwien.ac.at.
Funding
- Medical University of Vienna
Cite
APA
Jomrich, G., Yan, W., Kollmann, D., Kristo, I., Winkler, D., Puhr, H., Lhan-Mutlu, A., Hollenstein, M., Asari, R., & Schoppmann, S. F. (2024). Elevated fibrinogen-albumin ratio is an adverse prognostic factor for patients with primarily resected gastroesophageal adenocarcinoma. Journal of Cancer Research and Clinical Oncology. https://doi.org/10.1007/s00432-024-05976-z
Vancouver
Jomrich G, Yan W, Kollmann D, Kristo I, Winkler D, Puhr H, et al. Elevated fibrinogen-albumin ratio is an adverse prognostic factor for patients with primarily resected gastroesophageal adenocarcinoma. Journal of Cancer Research and Clinical Oncology. 2024. doi:10.1007/s00432-024-05976-z
BibTeX
@article{Jomrich2024,
author = {Jomrich, Gerd and Yan, Winny and Kollmann, Dagmar and Kristo, Ivan and Winkler, Daniel and Puhr, Hannah and Lhan-Mutlu, Aysegül and Hollenstein, Marlene and Asari, Reza and Schoppmann, Sebastian F},
title = {Elevated fibrinogen-albumin ratio is an adverse prognostic factor for patients with primarily resected gastroesophageal adenocarcinoma},
journal = {Journal of Cancer Research and Clinical Oncology},
year = {2024},
doi = {10.1007/s00432-024-05976-z}
}
EUVIMED